Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis

A. Bardia; S. Campos-Gomez; S. A. Hurvitz; Y. S. Lu; S. A. Im; F. Franke; L. Chow; P. Wheatley-Price; F. Melo Cruz; J. Alam; O. Kong; I. Diaz-Padilla; M. Miller; D. Tripathy

doi:10.1093/annonc/mdy272.320

Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis

A. Bardia, S. Campos-Gomez, S. A. Hurvitz, Y. S. Lu, S. A. Im, F. Franke, L. Chow, P. Wheatley-Price, F. Melo Cruz, J. Alam, O. Kong, I. Diaz-Padilla, M. Miller, D. Tripathy

Breast Medical Oncology

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	viii106-viii107
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy272.320
State	Published - Oct 1 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy272.320

Cite this

Bardia, A., Campos-Gomez, S., Hurvitz, S. A., Lu, Y. S., Im, S. A., Franke, F., Chow, L., Wheatley-Price, P., Melo Cruz, F., Alam, J., Kong, O., Diaz-Padilla, I., Miller, M., & Tripathy, D. (2018). Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii106-viii107. https://doi.org/10.1093/annonc/mdy272.320

Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis. / Bardia, A.; Campos-Gomez, S.; Hurvitz, S. A. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii106-viii107.

Research output: Contribution to journal › Article › peer-review

Bardia, A, Campos-Gomez, S, Hurvitz, SA, Lu, YS, Im, SA, Franke, F, Chow, L, Wheatley-Price, P, Melo Cruz, F, Alam, J, Kong, O, Diaz-Padilla, I, Miller, M & Tripathy, D 2018, 'Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii106-viii107. https://doi.org/10.1093/annonc/mdy272.320

Bardia A, Campos-Gomez S, Hurvitz SA, Lu YS, Im SA, Franke F et al. Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii106-viii107. doi: 10.1093/annonc/mdy272.320

Bardia, A. ; Campos-Gomez, S. ; Hurvitz, S. A. et al. / Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) : MONALEESA-7 subgroup analysis. In: Annals of oncology : official journal of the European Society for Medical Oncology. 2018 ; Vol. 29. pp. viii106-viii107.

@article{def19d7fb1f248e0ba3df6d5208af21e,

title = "Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis",

author = "A. Bardia and S. Campos-Gomez and Hurvitz, {S. A.} and Lu, {Y. S.} and Im, {S. A.} and F. Franke and L. Chow and P. Wheatley-Price and {Melo Cruz}, F. and J. Alam and O. Kong and I. Diaz-Padilla and M. Miller and D. Tripathy",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy272.320",

language = "English (US)",

volume = "29",

pages = "viii106--viii107",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC)

T2 - MONALEESA-7 subgroup analysis

AU - Bardia, A.

AU - Campos-Gomez, S.

AU - Hurvitz, S. A.

AU - Lu, Y. S.

AU - Im, S. A.

AU - Franke, F.

AU - Chow, L.

AU - Wheatley-Price, P.

AU - Melo Cruz, F.

AU - Alam, J.

AU - Kong, O.

AU - Diaz-Padilla, I.

AU - Miller, M.

AU - Tripathy, D.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85081532717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081532717&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy272.320

DO - 10.1093/annonc/mdy272.320

M3 - Article

C2 - 32136112

SN - 0923-7534

VL - 29

SP - viii106-viii107

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this